Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic
patients after treatment with SUs for 5 years, although SUs are widely used in type 2
diabetic patients. This study was designed to evaluate the effectiveness and safety of adding
compound preparation of pioglitazone and metformin for type 2 diabetic patients who have bad
glycemic control with the initial treatment of SUs.
Phase:
Phase 4
Details
Lead Sponsor:
Huazhong University of Science and Technology
Collaborators:
Hubei Xinhua Hospital Wuhan Iron and Steel Workers' Hospital Wuhan Pu-Ai Hospital